Targeting complement in atypical hemolytic and uremic syndrome: development and current status of eculizumab and ravulizumab

Until 2009, atypical hemolytic uremic syndrome (aHUS), a disease mediated by complement-induced endothelial activation, had a poor renal prognosis, with common progression to kidney failure and frequent recurrence after kidney transplantation, condem…

Preview only. Read the full abstract at the source